Last reviewed · How we verify

quinacrine dihydrochloride - Escalation dose

Neelesh Sharma MD PhD · Phase 1 active Small molecule

quinacrine dihydrochloride - Escalation dose is a Small molecule drug developed by Neelesh Sharma MD PhD. It is currently in Phase 1 development. Also known as: atabrine dihydrochloride, mepacrine dihydrochoride, SN 390.

At a glance

Generic namequinacrine dihydrochloride - Escalation dose
Also known asatabrine dihydrochloride, mepacrine dihydrochoride, SN 390
SponsorNeelesh Sharma MD PhD
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about quinacrine dihydrochloride - Escalation dose

What is quinacrine dihydrochloride - Escalation dose?

quinacrine dihydrochloride - Escalation dose is a Small molecule drug developed by Neelesh Sharma MD PhD.

Who makes quinacrine dihydrochloride - Escalation dose?

quinacrine dihydrochloride - Escalation dose is developed by Neelesh Sharma MD PhD (see full Neelesh Sharma MD PhD pipeline at /company/neelesh-sharma-md-phd).

Is quinacrine dihydrochloride - Escalation dose also known as anything else?

quinacrine dihydrochloride - Escalation dose is also known as atabrine dihydrochloride, mepacrine dihydrochoride, SN 390.

What development phase is quinacrine dihydrochloride - Escalation dose in?

quinacrine dihydrochloride - Escalation dose is in Phase 1.

Related